ARA-290 Ireland: Mechanism, Research Use and Handling

Author : Zubair Arain | Published On : 08 Oct 2026

ARA-290 Ireland: Mechanism, Research Applications and Handling Requirements

ARA-290 Ireland is a search term used by laboratories looking for cibinetide, an 11-amino-acid synthetic peptide modelled on a surface region of erythropoietin (EPO). The peptide has been designed to lack the haematopoietic activity of EPO while retaining interaction with the innate repair receptor, a heteromer of the EPO receptor and the β-common receptor (CD131). In preclinical models it has been studied for tissue-protective signalling, inflammation and cell survival pathways. This article covers its structure, proposed mechanism, the published animal and cell literature, laboratory applications, and the purity, storage and handling requirements for a research-use-only peptide.

What is ARA-290? Context for ARA-290 Ireland searches

ARA-290 is a linear synthetic peptide with the sequence pyroglutamyl-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, often written as pGlu-EQLERALNSS. Its average molecular weight is approximately 1,257 daltons. It is also known by its international nonproprietary name, cibinetide. The N-terminus is a cyclised glutamine residue, pyroglutamic acid, which blocks the free amino group and gives some protection against aminopeptidases. The sequence contains no methionine, cysteine or tryptophan, which makes it chemically less oxidation-prone than many research peptides, although glutamine and asparagine residues introduce a deamidation risk discussed later.

The peptide originates from work on the tertiary structure of erythropoietin. EPO is a glycoprotein of roughly 30 kilodaltons, well known for stimulating red blood cell production through the homodimeric EPO receptor. Researchers including Michael Brines and Anthony Cerami, working in the early 2000s, reported that EPO also protected tissues in experimental injury models, and that this activity appeared to involve a different receptor complex from the one that drives erythropoiesis. They then designed small peptides that mimic part of the protein's three-dimensional surface, specifically the aqueous face of helix B, so that the tissue-protective activity could be separated from the effects on red cell production. ARA-290 emerged from that programme.

Because it is built from standard proteinogenic amino acids plus the pyroglutamate terminus, ARA-290 is produced by Fmoc solid-phase peptide synthesis. The chain is assembled on a resin, cleaved with trifluoroacetic acid, purified by reversed-phase high-performance liquid chromatography and lyophilised. A pyroglutamate terminus can be introduced directly using a pyroglutamic acid building block or formed from an N-terminal glutamine, and this detail matters analytically, as covered below.

Mechanism of action

The proposed target of ARA-290 is the innate repair receptor (IRR), also described as the tissue-protective receptor. This is a heteromeric complex of the EPO receptor subunit and the β-common receptor subunit (CD131), which is shared with the receptors for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor. The conventional haematopoietic EPO receptor is a homodimer of two EPO receptor chains. The heteromer is thought to form under conditions of cellular stress or injury, and it has been reported in tissues including neurons, the heart and the kidney. EPO binds both receptor types, whereas the helix B-derived peptides were designed to engage the heteromer preferentially.

Receptor engagement in this model is reported to activate intracellular signalling cascades associated with cell survival, including Janus kinase 2 (JAK2), phosphoinositide 3-kinase and Akt, and the signal transducer and activator of transcription 5 pathway. Downstream, the reported effects in cell and animal models include reduced apoptotic signalling and reduced production of pro-inflammatory cytokines such as tumour necrosis factor alpha and interleukin-1β. In effect, the peptide is studied as a modulator of the interface between injury, inflammation and cell survival at the receptor level.

Several cautions apply. The existence and composition of the innate repair receptor remain a topic of active discussion, and not every laboratory has reproduced the receptor findings. The peptide is also short-lived in biological fluids, with a plasma half-life reported in the order of minutes, so sustained signalling in animal models depends on dosing design rather than any intrinsic persistence. Finally, because small structural impurities can change receptor binding, any attempt to interpret signalling data depends on the material being what its label claims. A truncated or deamidated variant could have different affinity or none, which would confound conclusions about the receptor pathway itself.

What the research shows

The preclinical literature on ARA-290 and related helix B peptides spans cell culture and several rodent models. The summaries below are given in general terms, and readers should consult the original papers for methods, doses, routes and statistics. Dosing details are deliberately not reproduced here because they differ between models and publications.

The first area is the original design and characterisation of the peptides. Brines and colleagues published work in Proceedings of the National Academy of Sciences in 2008 describing nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. The models included cell assays and rodent models of tissue injury, and the observation was that the helix B-derived peptides retained protective activity in those models without stimulating red blood cell production. The work established the rationale for the whole family of compounds. Readers can locate it through a PubMed search for the 2008 Brines study on nonerythropoietic tissue-protective peptides.

The second area is the receptor mechanism. An earlier study from the same group, published in PNAS in 2004, reported that EPO-mediated tissue protection required a receptor complex containing both the EPO receptor and the β-common receptor, rather than the EPO receptor homodimer alone. The models included cell-based and animal systems with genetic and pharmacological approaches to separate the two receptor forms. This paper is the main reference for the heteromer hypothesis that later helped define the proposed target for ARA-290. It can be found through a PubMed search for the 2004 Brines study on the EPO and common β-subunit heteroreceptor.

The third area is cardiac ischaemia. Ahmet and colleagues reported in Molecular Medicine that a small helix B surface peptide based on the EPO structure was cardioprotective against ischaemic myocardial damage in rodent models. The model involved experimental coronary occlusion and reperfusion in rodents, and the observation was a reduction in markers of tissue damage relative to controls. The study is useful to laboratories because it tested a short peptide, rather than the full protein, in a surgically induced injury model.

The fourth area is a general one. Several groups have used rodent models of neuropathic injury and of metabolic stress to examine how helix B peptides affect nerve function, inflammatory signalling and islet cell survival. The reported observations include altered behavioural responses to stimuli in mice and changes in inflammatory markers in tissue. Because these studies differ in species, injury method, timing and measured endpoints, they are best treated as hypothesis-generating work. Independent replication across multiple laboratories is still developing, and researchers should read individual papers critically before extrapolating between models.

Research applications

In cell biology, ARA-290 is used as a ligand to probe signalling downstream of the proposed innate repair receptor. Typical experiments apply the peptide to cultured neuronal, cardiac, renal or immune cells under stress conditions, such as oxygen-glucose deprivation or exposure to inflammatory stimuli, and measure phosphorylation of JAK2, Akt and STAT5 or changes in apoptosis markers. Knockdown or knockout of the EPO receptor or CD131 provides the controls needed to test receptor dependence.

In immunology and inflammation research, the peptide is applied to macrophage and monocyte cultures to examine cytokine production and polarisation. These assays are sensitive to endotoxin contamination, so batch-specific endotoxin data are often requested.

In animal pharmacology laboratories operating under appropriate licences, the peptide has been used in models of ischaemia-reperfusion injury, neuropathic injury and metabolic stress, mainly to study mechanism and biomarker responses. These applications fall outside the scope of in-vitro supply and are mentioned only to describe the published literature.

In analytical chemistry, the peptide serves as a useful case for method development. Its pyroglutamate terminus, glutamine and asparagine content, and absence of oxidation-prone residues make it a practical test for separating deamidated and cyclisation-related variants by reversed-phase HPLC and mass spectrometry. In structural and biophysical work, short helix-derived peptides are used to examine conformational behaviour in solution by circular dichroism and NMR, since helix B peptides are designed to mimic a segment of a larger folded protein.

Across all of these contexts, the shared requirement is material with a documented identity, purity and batch history.

Purity, storage and handling

Verification begins with reversed-phase HPLC, which separates the target peptide from synthesis-related impurities and reports purity as the percentage of total peak area at a stated wavelength, usually 214 or 220 nm. A purity figure is only meaningful when the chromatogram, gradient and detection conditions are supplied. Identity is confirmed separately by mass spectrometry, where the observed mass should match the calculated value of about 1,257 daltons. For this sequence, laboratories should look for characteristic shifts. A deamidation product of glutamine or asparagine appears about 1 dalton higher, which is small and requires adequate mass resolution to resolve. A peptide with an uncyclised N-terminal glutamine in place of pyroglutamate appears about 17 daltons higher. Net peptide content, determined by amino acid analysis or nitrogen analysis, is also important because peptides purified with trifluoroacetic acid are supplied as TFA salts, and the counterion contributes to the weight of the powder.

A batch-specific certificate of analysis matters because peptide synthesis is a per-run process. Yields, impurity profiles and salt content vary between syntheses, so a generic specification sheet describes an intention, whereas a batch certificate describes the powder in the vial. It should carry a lot number matching the label, method details and an analysis date. Because degradation accelerates once a peptide is reconstituted, batch-level HPLC verification matters for a sequence containing glutamine and asparagine, both of which can deamidate in solution. Laboratories sourcing ARA-290 Ireland should expect a batch-specific certificate of analysis and lyophilised storage at -20 °C, and the same documentation standard applies when comparing the most trusted peptide supplier Ireland researchers may shortlist.

Lyophilised powder is the most stable form because the absence of water slows hydrolysis and deamidation. Long-term storage at -20 °C is standard, with -80 °C used where maximum stability is required. Vials should equilibrate to room temperature in a desiccator before opening, because condensation on cold powder introduces moisture that shortens shelf life. Exposure should be brief and vials resealed promptly, as the glutamic acid and arginine residues make the peptide hydrophilic and prone to absorbing water.

Light sensitivity is a lesser concern for this sequence than for peptides containing tryptophan or methionine, since it has no strongly photo-reactive residues. Storage in the dark in an amber vial or in foil is still a sensible precaution, particularly over long periods.

Reconstituted peptide is far less stable than the dry powder. Solutions are best prepared in a buffer or solvent suited to the sequence, divided into single-use aliquots to avoid repeated freeze-thaw cycles, and stored frozen. Deamidation rates depend on pH, temperature and the neighbouring residues, with the asparagine-serine pair in this sequence being a recognised site. Stability windows are short, often days to a few weeks, and should be established empirically for each solvent and temperature by repeat HPLC analysis. Near-neutral or slightly acidic buffers are commonly used to limit base-catalysed deamidation. Low-binding tubes reduce losses through adsorption to plastic and glass surfaces.

On receipt, laboratories should check that seals are intact, transfer the material to cold storage promptly, and record the receipt date and storage conditions against the lot number so that any later anomaly can be traced. For consignments entering Ireland, documented packaging and shipping times matter because transit conditions are outside the laboratory's control.

Frequently asked questions

What is the amino acid sequence and molecular weight of ARA-290?

ARA-290 is an 11-residue peptide with the sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, where pGlu is pyroglutamic acid. Its average molecular weight is approximately 1,257 daltons. It is derived from helix B of erythropoietin, and mass spectrometry should confirm the observed mass against this calculated value.

How should lyophilised ARA-290 be stored in a laboratory?

Lyophilised material is generally stored sealed, dry and protected from light at -20 °C for long-term storage, or colder for extended periods. Vials should warm to room temperature in a desiccator before opening to prevent condensation. Moisture is the main risk because it drives deamidation of the glutamine and asparagine residues.

How stable is reconstituted ARA-290 in solution?

Dissolved peptide degrades much faster than the lyophilised powder, mainly through deamidation and hydrolysis. Stability depends on solvent, pH and temperature, so it should be tested by repeat HPLC. Single-use aliquots stored frozen, with repeated freeze-thaw cycles avoided, are the usual way to limit loss in research settings.

What should a certificate of analysis for ARA-290 show?

A complete certificate lists the sequence, lot number, HPLC purity with chromatogram and method, measured versus theoretical mass, appearance and counterion form. Better documents add net peptide content, water content and endotoxin data where relevant, so that working concentrations can be calculated accurately for cell-based assays.

This peptide is supplied for in-vitro laboratory research only. It is not a medicine, is not intended for human or veterinary use, and must not be administered to people or animals. Researchers remain responsible for complying with institutional, safety and regulatory requirements in their jurisdiction.